Checkpoint immunotherapies targeting the CTLA-4 and PD-1 pathways have been approved for several cancers and have helped many patients. When they’re used together, they can work even better because they target non-redundant pathways. There are other checkpoints as well, including LAG-3, which Dr. Teague is targeting, alone and with anti-CTLA-4 and anti-PD-1 immunotherapies. Altogether, he’s testing 8 different combinations to see which work best. He’s also characterizing the activity of different pathways under each of these conditions, to see how they influence outcomes. This will hopefully provide doctors with clues about which combinations might work well in humans as well as provide biomarkers to predict which patients are more likely to respond.
Projects and Grants
Defining the mechanisms of human T cell rescue by checkpoint blockade immunotherapy
Saint Louis University School of Medicine | All Cancers | 2014
¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.